The Rapidly Changing Treatment Paradigm for Stage III Non-Small Cell Lung Cancer

Recorded: August 27, 2025

Stage III non-small cell lung cancer (NSCLC) is a commonly encountered disease among those diagnosed with lung cancer. Over the past five years, there have been significant changes in how this disease is managed, including adjuvant targeted therapy after surgical resection and neoadjuvant chemoimmunotherapy before surgery, along with a myriad of approaches in those who are either nonoperable or nonresectable. All approaches rely on preoperative comprehensive genomic profiling of diagnostic specimens prior to making treatment decisions. This webinar reviews all aspects of treatment for stage III NSCLC, with special emphasis on the multidisciplinary approach to this disease.

This non-CME education is brought to you by CHEST and sponsored by AstraZeneca.

Watch Part 1: Early-Stage NSCLC: Advances in Diagnosis, Tissue Acquisition, and Treatment »